Home Tags MGC018

Tag: MGC018

Photo: Photo ASCO meeting. Photo Courtesy: ASCO/Todd Buchanan 2015

ASCO 2020 – Promising Development in the Advancement of Antibody-drug Conjugates

With an increasing number of antibody-drug conjugates (ADC) being approved and commercially available for the treatment of patients with cancer and hematological malignancies, the...
Featured Image: Scientist in Biomedical Laboratory. Courtesy 2019 Fotolia. used with permission.

Rapid Advances in the Development of Novel ADCs Targeting B7-H3 and...

With five antibody-drug conjugates (ADC) having received approval from the United States Food and Drug Administration (FDA) and other regulators around the world and...

MacroGenics and Synthon Biopharmaceuticals Sign Agreement

MacroGenics and Synthon Biopharmaceuticals have signed an agreement  to license and collaborate in he development of MGC018, an antibody-drug conjugate or ADC directed against...